Last reviewed 2026-04-23 · How we verify

BIND-014

BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway.

BIND-014 is a targeted delivery system for small interfering RNA (siRNA) that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive.

At a glance

Mechanism of action

BIND-014 uses a proprietary nanoplatform to deliver siRNA that targets the PD-1/PD-L1 pathway, potentially inhibiting the immune checkpoint and enhancing anti-tumor activity. This approach aims to selectively deliver the therapeutic siRNA to tumor cells, reducing off-target effects and improving efficacy.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive

Common side effects

• Injection site reactions

Key clinical trials

• A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer (PHASE2)
• A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE2)
• A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer (PHASE2)
• A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (PHASE2)
• A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.